NME: COX-2 inhibitor for rheumatoid arthritis, osteoarthritis, and dysmenorrhea
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Medicare Plans Face Higher Liability From Cap on Out-of-Pocket Drug Costs
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
Listen
Medication Prior Authorization Biggest Daily Challenge for 1 in 5 Prescribers, Survey Says
FDA Approves First Treatment for Chronic Inflammatory Lung Condition
FDA Approves Ajovy for Childhood Migraine Prevention
FDA Grants Accelerated Approval For Targeted Drug for Rare Brain Tumor